A study to investigate the preventive effect of AG-1749 against the onset of gastric and duodenal ulcers that can be seen during long-term treatment with nonsteroidal anti-inflammatory drugs (NSAID).

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220485

Enrollment

602

Registered

2007-12-13

Start date

2007-12-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients that require long-term NSAID treatment to manage pain.

Interventions

investigational material(s) Generic name etc : AG-1749 (Lansoprazole) INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investiga

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patient was on NSAID treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started. 2) The patient was confirmed to have a history of gastric ulcer or duodenal ulcer (combined gastric and duodenal ulcer is also possible).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Frequency of gastric or duodenal ulcer	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026